The Brucella abortus L71L12 ribosomal gene was amplified by PCR and subcloned into the prokaryotic expression vector pMAL-c2. Escherichia coli DH5a was transformed with the pMAL-L7/L12 construct, and 
Brucella abortus is a gram-negative intracellular bacterium infecting animals and humans (19) . B. abortus infection causes spontaneous abortions in cattle and persistent undulant fever, endocarditis, arthritis, and meningitis in humans (27) . Little is known regarding the cellular and molecular mechanisms used by B. abortus to penetrate and resist destruction within the macrophage, the principal host cell of residence for the bacterium. Gamma interferon is a cytokine produced by activated T lymphocytes and NK cells that plays an important role in antimicrobial activity through macrophage activation (1) . This cytokine is capable of upregulating major pathways described for microbial killing by macrophages (4, 18, 24) . Because B. abortus resides and replicates within the cytoplasm of mononuclear phagocytes and that cytokines such as gamma interferon upregulate macrophage killing activity, a T-lymphocyte-mediated response is crucial for host protection.
Few B. abortus genes have been cloned and the proteins that they encode have been characterized (6, 12, 15, 23, 29) . Furthermore, little is understood regarding the importance of these bacterial proteins in the immune response. In addition, the potential for these proteins to elicit a protective cellular response against bovine brucellosis has not been investigated. Therefore, a greater understanding of the relationship of bacterial proteins-with host protection and disease is required. Given that lymphocytes proliferate to bacterial antigens and that cytokines activate macrophage killing of intracellular bacteria, the identification of individual B. abortus proteins that trigger T lymphocytes is crucial to define how the immune system functions in this disease. At present, there is no information regarding recombinant B. abortus proteins that are able to activate a specific T-cell subset critical for providing host protection against this bacterium. This paper describes the subcloning of the L7/L12 ribosomal gene from B. abortus, its expression in Escherichia coli, and the bovine T-lymphocyte recognition of the recombinant protein produced. was discarded. The cell pellet was frozen in a dry ice-methanol bath at -70°C and allowed to thaw to 37°C. The pellet was resuspended in 100 ml of phosphate buffer saline (PBS; pH 8.4) containing 25 mg of lysozyme. The resuspended pellet was frozen and thawed three more times. The resulting suspension was homogenized to achieve uniformity and then incubated at 37°C for 30 min, with homogenization every 10 min. The suspension was centrifuged at 9,000 x g for 30 min, and the supernatant containing crude extract was loaded onto a polyacrylamide gel to confirm the presence of the expressed fusion protein by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). E. coli lysates containing the induced MBP-L7/L12 fusion protein were diluted 1:5 with PBS. Then, the suspension was loaded into an amylose resin column (New England Biolabs) and washed 10 times with PBS, and the fusion protein was eluted with PBS plus 10 mM maltose. The purified fusion protein was cleaved with factor Xa protease, which recognizes a specific amino acid sequence between the maltose-binding protein (MBP) and the L7/L12 protein. After cleavage, recombinant L7/L12 (rL7/L12) was purified by rebinding of MBP to the amylose resin. Pure rL7/L12 was concentrated in PBS, using a centricon-10 microconcentrator (AMICON, Beverly, Mass.), and the protein concentration was determined by a Bio-Rad (Hercules, Calif.) protein assay.
For SDS-PAGE lysates from induced and uninduced E. coli carrying the pMAL-L7/L12 construct, purified and cleaved MBP-L7/L12 fusion protein, pure MBP, and purified rL7/L12 were solubilized in sample buffer containing 2% SDS and 5% 2-mercaptoethanol and processed according to the method of Laemmli (10) . Before electrophoresis an equal volume of 2x concentrated sample buffer was added, and the mixture was boiled for 3 min and loaded onto the gel. Protein samples and molecular weight markers were analyzed on SDS-15% PAGE gels and visualized by Coomassie blue staining.
For Western blot (immunoblot) analysis, the gels were electroblotted onto nitrocellulose at 75 V for 2 h. Transfers were carried out in 25 mM Tris-192 mM glycine-20% methanol (3, 26) . The blotted nitrocellulose was blocked with skim milk for 2 h. Then, rabbit anti-MBP serum was used at a 1:5,000 dilution during incubation for 2 h (at room temperature). After reactions with the primary antibody, the blots were washed three times with TBST (0.5 M NaCl-0.02 M Tris [pH 7 .5], 0.05% Tween 20) and incubated for 1 h with a goat anti-rabbit immunoglobulin G-alkaline phosphatase conjugate (Promega) at a 1:10,000 dilution in TBST. Then, the blots were washed three times with TBST, and the reactions were developed by using nitroblue tetrazolium and BCIP (5-bromo-4-chloro-3-indolyl-1-phosphate) purchased from Promega.
To express the B. abortus L7/L12 gene in E. coli, PCR amplification of the target gene was done with further subcloning of L71L12 into pMAL-c2. This vector expresses foreign sequences as a fusion protein with the 42.7-kDa MBP (8) .
Expression of a 55-kDa fusion protein was observed by SDS-PAGE containing lysates from IPTG-induced E. coli that contained the pMAL-L7/L12 construct (Fig. 1A) . To confirm that the expressed fusion protein was MBP-L7/L12, Western blot analysis was performed, using rabbit anti-MBP antibody. Figure 1B shows the anti-MBP recognition of the MBP-L7/L12 fusion protein. After expression, the fusion protein was purified in an amylose affinity column, and the interval necessary for cleavage of L7/L12 from MBP was determined by kinetic experiments at 2, 4, 8, 14 h with factor Xa treatment. Incubation of factor Xa protease with the fusion protein for 14 h resulted in total cleavage of MBP from L7/L12 (Fig. 2) . Cleavage of the fusion protein shown in Fig. 2 kDa, respectively. rL7/L12 was purified by rebinding MBP to the amylose resin. Figure 3A shows the isolated rL7/L12 on an SDS-PAGE after purification. Western blot analysis demonstrated that the anti-MBP antibody did not recognize the separated rL7/L12 (Fig. 3B) .
Peripheral blood mononuclear (PBM) cells were isolated from cattle blood samples by density gradient centrifugation with Lymphoprep (Nycomed AS Diagnostics, Olso, Norway). The cells were washed three times with PBS containing 100 U of penicillin per ml and 100 ,ug of streptomycin per ml. The PBM cells were then suspended in RPMI 1640 (Sigma Chemical Co., St. Louis, Mo.) supplemented with 2 mM L-glutamine, 25 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid), 50 ,uM 2-mercaptoethanol, 100 U of penicillin per ml, 100 ,ug of streptomycin per ml, and 10% heat-inactivated fetal bovine serum (Sigma Primed bovine PBM cells from three different animals proliferated to the rL7/L12 protein, whereas cells from the naive group did not (Fig. 4) . Concanavalin A was used as a T-cell-activating control in this experiment, and the counts from both the naive and vaccinated group were above 100,000 cpm (data not shown). The lymphocyte population engaged in this response was analyzed by flow cytometry. Phenotypic surface analysis was conducted on proliferating cells 7 SBU-T8 (anti-CD8 [14] ), 86D (anti--y5 T-cell receptor [13] ), and 33 (anti-bovine IgM [20] ). The cells that proliferated in response to the recombinant protein (their approximate percentages ± standard deviations are given in parentheses) were CD4+ (20.7% ± 0.8%), CD8+ (13.2% ± 1.6%), IgM (10.7% ± 2.1%), and -yb-T-cell receptor (4.5% ± 1.0%). We detected a twofold increase in the percentage of CD4+ T lymphocytes when PBM cells were stimulated in vitro with the rL7/L12 (20.7% ± 0.8%) compared with cells cultured in medium alone (10.8% ± 1.5%). However, no significant change in the percentage of the other cell types was detected (data not shown).
In this study, we have subcloned and expressed a B. abortus DNA fragment which encodes the L7/L12 ribosomal protein previously shown to be immunodominant in cattle (3) . The L7/L12 gene encodes a 50S ribosomal protein and is essential in bacterial ribosomes for the proper function of factors involved in protein synthesis, such as elongation factor G and elongation factor Tu (11) . L7/L12 consists of an N-terminal domain that anchors the L10 ribosomal protein and a Cterminal domain which is important in the binding of elongation factors G and Tu. The L7/L12 ribosomal protein is essential for the maximal rate of protein synthesis and the low frequency of errors (22) .
The in vivo prokaryotic protein expression system used here produced large amounts of the recombinant fusion polypeptide and proved to be a suitable system for expressing foreign sequences and purifying the resultant fusion protein. The pMAL-c2 vector has been used for gene expression of other immunodominant proteins, such as the GroES heat shock protein from Mycobactenum leprae (16 (17) .
Ribosomal preparations from several pathogens, including B. abortus, have been shown to be highly protective vaccines (7) . However, the components of these preparations have not (9) . The mechanism by which the host responds to and eliminates infection is a central issue in our understanding of the immune response to pathogens. For many intracellular organisms, such as B. abortus, T-cell-mediated immunity is critical for host protection. Because T cells play a major role in protection against Brucella infection through cytokine secretion, such as that of gamma interferon (17) , the identification of specific Brucella antigens that induce a T-lymphocyte response is an important element in designing new molecular candidate vaccines. Soluble Brucella proteins have been isolated and tested for their ability to stimulate primed murine T lymphocytes by cell proliferation and cytokine production (28) . These fractions induced T-lymphocyte proliferation and elicited gamma interferon production by CD4+ T cells, but none of the proteins have been purified and characterized, suggesting that a number of proteins rather than a single moiety possess these antigenic determinants.
This is the first report of a B. abortus T-cell-reactive ribosomal protein. However, further characterization of the Tlymphocyte subset involved in this response by phenotypic surface analysis and cytokine profile is required. Identifying proteins from a given pathogen that favor a T-cell response and the desired cytokine profile may provide important approaches for diagnosis and alternative vaccine strategies. Subcloning and expression of the B. abortus L7!L12 gene provides an opportunity to immunologically characterize a specific ribosomal protein which may clarify why ribosomal vaccines confer protection against intracellular pathogens. 
